Cysteine cathepsins and the skeleton

Keyphrases

• Protease 100%
• Drug Target 100%
• Cathepsin K 100%
• Collagenase Activity 100%
• Cysteine Cathepsins 100%
• Autoimmune 50%
• Clinical Trials 50%
• Immune Response 50%
• Glycoprotein 50%
• Pharmaceutical Industry 50%
• Immune-related 50%
• Anti-inflammatory Drugs 50%
• Phase II Trial 50%
• Lysosomotropic Agents 50%
• Cathepsin Inhibitor 50%
• Bone Resorption 50%
• Nitriles 50%
• Extracellular Matrix Protein 1 (ECM1) 50%
• Housekeeping 50%
• Cathepsin S 50%
• Bone Mineral Density 50%
• Osteoporosis 50%
• Bone Remodeling 50%
• Cartilage 50%
• Extracellular Matrix Degradation 50%
• Specialized Functions 50%
• Osteoclast 50%
• Bone Formation 50%
• Serum Markers 50%
• Joint Disease 50%
• Inflammatory Immune Response 50%
• Odanacatib 50%
• Lysosomal Acid Lipase 50%
• Arthritis Diseases 50%
• Formation Process 50%
• Urinary Markers 50%
• Collagen Degradation 50%
• Cathepsin K Inhibition 50%
• Type II Collagen 50%
• Protease Family 50%
• Osteoclast Activity 50%
• Tissue-specific Function 50%
• MHC Class II Antigen Presentation 50%
• Mineral Reduction 50%
• Industry-led 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Proteinase 100%
• Cysteine 100%
• Cathepsin 100%
• Collagenase 66%
• Cathepsin K 66%
• Diseases 66%
• Clinical Trial 33%
• Glycoprotein 33%
• Antiinflammatory Agent 33%
• Cathepsin S 33%
• Arthropathy 33%
• Odanacatib 33%
• Scleroprotein 33%
• Cathepsin K Inhibitor 33%
• Nitrile 33%
• Collagen Type 2 33%
• Phase III Trials 33%